In addition, somatic activating HER2 mutations have been detected in HER2+ breast cancer patients subjected to ongoing SUMMIT “basket” trial of Neratinib (NCT01953926), suggesting hyperactivation of HER family kinases may confer resistance to Neratinib [13]. This evidence concerns the gene ERBB2 and breast carcinoma.